New Blood-Based Screening Test for Colorectal Cancer

COLOGIC, developed in Canada, helps eliminate traditional barriers to screening

 CML HealthCare Inc. (TSX:CLC) today announced the introduction of COLOGIC, a new and simple blood test used to assess the risk of colorectal (colon) cancer. Colorectal cancer is the second leading cause of cancer death in Canada. Last year alone, over 9,000 Canadians died from the disease. More tragic, perhaps, is that colorectal cancer death is preventable with appropriate screening and treatment. Early detection most often leads to a complete recovery. An estimated 23,000 Canadians will be diagnosed this year, many with advanced disease. Because most people do not experience any symptoms in the early stages, appropriate screening is critical.

Rosetta Genomics Expands Management Team, Laboratory Capacities and Commercial Operations

Prepares for Anticipated Growth for Award-Winning, Next-Generation microRNA Diagnostics

Rosetta Genomics Ltd. (ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced the completion of three executive hires and an expansion of its commercial  operations in preparation for expected sales growth of its microRNA diagnostic assays, specifically its flagship product miRview® mets2.  The Company recently announced a co-marketing agreement with Precision Therapeutics, Inc. for miRview® mets2, as well as a recent decision by Medicare to reimburse the miRview® mets2 assay.

Nanosphere Receives FDA Authorization to Market Its Gram-Positive Blood Culture Test

First of Its Kind Test to Launch Immediately

Nanosphere, Inc. (NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today the U.S. Food and Drug Administration has granted a de novo petition permitting marketing of its Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) on the automated sample-to-result Verigene(R) System.

The BC-GP test notably expands Nanosphere's infectious disease test capabilities to include fast detection of bacteria that can cause deadly bloodstream infections, an increasingly recognized health threat.

Genetic Technologies Provides BREVAGen(TM) Sales and Reimbursement Update

Strong Start to 2012 With BREVAGen(TM) Credentialing Now Reaching 13 Million Covered Lives

Genetic Technologies Limited (GTG.AX) (GENE) is pleased to provide an update on BREVAGen™ sales and the "credentialing" process with the top ten U.S. Preferred Provider Organizations ("PPOs"). To date, the Company has executed credentialing contracts with four PPOs which represents an estimated 13 million covered lives in the U.S. Progress with these leading PPOs has been a key driver of improved BREVAGen™ revenue collection.

Total revenue received from BREVAGen™ sales in the period from January to April 2012 represented over 63% of all revenues received since the test was launched in June 2011.